Allurion shares plunge 30.68% intraday as NYSE initiates delisting proceedings over failure to meet $50M equity/market cap requirements.

Allurion Technologies Inc. fell 30.68% intraday after the New York Stock Exchange initiated delisting proceedings against the company for failing to meet continued listing standards under Section 802.01B, which require at least $50 million in shareholders’ equity or market capitalization. The NYSE determined Allurion could not demonstrate compliance within the extended plan period, prompting the delisting notice. While the company intends to appeal and expects shares to remain listed during the process, the announcement triggered a sharp selloff as investors reacted to the heightened risk of delisting and uncertainty over its ability to regain compliance or secure alternative listings. The stock’s decline reflects market concern over regulatory challenges and the company’s ongoing financial struggles.